Tepavac A, Secen N, Sazdanic Velikic D, Popovic G, Perin B
Department of Chemotherapy, Institute of Pulmonary Diseases of Vojvodina, Sremska Kamenica, Medical Faculty, University of Novi Sad, Serbia.
J BUON. 2010 Oct-Dec;15(4):679-83.
the aim of this study was to evaluate the influence of atelectasis (AT) on overall survival of patients with non small cell lung cancer (NSCLC).
the study included patients of both sexes with unresectable stage III and IV NSCLC with good performance status (PS) (ECOG ≤ 2). Patients were divided into two groups: with AT (AT+) and without AT (AT-): Factors analyzed included sex, age, histologic type, ECOG performance status, stage of disease and treatment modality. Overall survival was estimated according to Kaplan-Meier method, and multivariate analysis was used to identify independent prognostic factors.
we evaluated 247 patients (83% males and 17% females); 47/247 (19%) of patients belonged to AT+ group. In this group 21% of patients had stage IIIA, 46% IIIB stage, and 33% IV stage. Overall survival was significantly longer in the AT+ group (15.23 vs. 9.03 months, p=0.001). AT+ patients in stages III and IV had significantly longer overall survival than AT- patients in the same stages (p=0.001, p=0.002, respectively). Multivariate analysis showed that atelectasis (p=0.001), stage of disease (p=0.001), and treatment modality (p=0.005) were independent prognostic factors associated with survival.
atelectasis is favorable prognostic factor concerning overall survival in patients with NSCLC.
本研究旨在评估肺不张（AT）对非小细胞肺癌（NSCLC）患者总生存期的影响。
该研究纳入了不可切除的Ⅲ期和Ⅳ期NSCLC且体能状态良好（PS）（东部肿瘤协作组体能状态评分≤2）的患者，性别不限。患者被分为两组：有肺不张组（AT+）和无肺不张组（AT-）。分析的因素包括性别、年龄、组织学类型、东部肿瘤协作组体能状态评分、疾病分期和治疗方式。采用Kaplan-Meier法估计总生存期，并进行多因素分析以确定独立的预后因素。
我们评估了247例患者（男性占83%，女性占17%）；47/247（19%）例患者属于AT+组。该组中21%的患者为ⅢA期，46%为ⅢB期，33%为Ⅳ期。AT+组的总生存期明显更长（15.23个月对9.03个月，p = 0.001）。Ⅲ期和Ⅳ期的AT+患者的总生存期明显长于相同分期的AT-患者（分别为p = 0.001，p = 0.002）。多因素分析显示，肺不张（p = 0.001）、疾病分期（p = 0.001）和治疗方式（p = 0.005）是与生存相关的独立预后因素。
肺不张是NSCLC患者总生存期的有利预后因素。
